NDC 67684-1901 Lipiodol

Ethiodized Oil

NDC Product Code 67684-1901

NDC 67684-1901-1

Package Description: 1 AMPULE in 1 CARTON > 10 mL in 1 AMPULE

NDC 67684-1901-2

Package Description: 1 VIAL in 1 CARTON > 10 mL in 1 VIAL

NDC Product Information

Lipiodol with NDC 67684-1901 is a a human prescription drug product labeled by Guerbet Llc. The generic name of Lipiodol is ethiodized oil. The product's dosage form is injection and is administered via intra-arterial; intralymphatic; intrauterine form.

Labeler Name: Guerbet Llc

Dosage Form: Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Lipiodol Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • ETHIODIZED OIL 480 mg/mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • POPPY SEED OIL (UNII: 9G3Z76ES9J)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intra-arterial - Administration within an artery or arteries.
  • Intralymphatic - Administration within the lymph.
  • Intrauterine - Administration within the uterus.

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Guerbet Llc
Labeler Code: 67684
FDA Application Number: NDA009190 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 03-21-2014 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Lipiodol Product Label Images

Lipiodol Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

  • Lipiodol is an oil-based radio-opaque contrast agent indicated for:hysterosalpingography in adultslymphography in adult and pediatric patientsselective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

2.1 Dosing Guidelines

  • Draw Lipiodol into a glass syringe.
  • Use the smallest possible amount of Lipiodol according to the anatomical area to be visualized.
  • HysterosalpingographyUsing aseptic technique inject Lipiodol into the endometrial cavity with fluoroscopic control. Inject increments of 2 mL of Lipiodol until tubal patency is determined; stop the injection if patient develops excessive discomfort. Re-image after 24 hours to establish whether Lipiodol has entered the peritoneal cavity.
  • Before using Lipiodol exclude the presence of these conditions: pregnancy, uterine bleeding and endocervicitis, acute pelvic inflammatory disease, the immediate pre-or postmenstrual phase or within 30 days of curettage or conization.
  • LymphographyInject Lipiodol into a lymphatic vessel under radiologic guidance to prevent inadvertent venous administration or intravasation. Adults:unilateral lymphography of the upper extremities 2 to 4 mLunilateral lymphography of the lower extremities 6 to 8 mLpenile lymphography 2 to 3 mLcervical lymphography 1 to 2 mLPediatric patients:Inject a minimum of 1 mL to a maximum of 6 mL according to the anatomical area to be visualized. Do not exceed 0.25 mL/kg.The following method is recommended for lymphography of the upper or lower extremities. Start the injection of Lipiodol into a lymphatic channel at a rate not to exceed 0.2 mL per minute. Inject the total dose of Lipiodol in no less than 1.25 hours. Use frequent radiologic monitoring to determine the appropriate injection rate and to follow the progress of Lipiodol within the lymphatics. Interrupt the injection if the patient experiences pain. Terminate the injection if lymphatic blockage is present to minimize introduction of Lipiodol into the venous circulation via lymphovenous channels. Terminate the injection as soon as Lipiodol is radiographically evident in the thoracic duct to minimize entry of Lipiodol into the subclavian vein and pulmonary embolization. Obtain immediate post-injection images. Re-image at 24 or 48 hours to evaluate nodal architecture.Selective Hepatic Intra-arterial InjectionDetermine the dose depending on the tumor size, local blood flow in the liver and in the tumor(s).Inject from 1.5 to 15 mL slowly under continuous radiologic monitoring. Stop the injection when stagnation or reflux is evident. Limit the dose to only the quantity required for adequate visualization. The total dose of Lipiodol administered should not exceed 20 mL.

2.2 Drug Handling

Inspect Lipiodol visually for particulate matter and discoloration before administration. Do not use the solution if particulate matter is present or if the container appears damaged. Lipiodol is a clear, pale yellow to amber colored oil; do not use if the color has darkened.Draw Lipiodol into a glass syringe and use promptly. Discard any unused portion of Lipiodol.

3 Dosage Forms And Strengths

Each milliliter of Lipiodol contains 480 mg/mL of Iodine organically combined with ethyl esters of fatty acids of poppy seed oil.

4 Contraindications

Lipiodol is contraindicated in patients with hypersensitivity to Lipiodol, hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding. HysterosalpingographyLipiodol hysterosalpingography is contraindicated in pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre-or postmenstrual phase, or within 30 days of curettage or conization.LymphographyLipiodol Lymphography is contraindicated in patients with a right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to the examined area.Selective Hepatic Intra-arterial Use Patients with HCCLipiodol use is contraindicated in areas of the liver where the bile ducts are dilated unless external biliary drainage was performed before injection.

5.1 Pulmonary And Cerebral Embolism

Pulmonary embolism may occur immediately or after a few hours to days from inadvertent systemic vascular injection or intravasation of Lipiodol and cause decreased pulmonary diffusing capacity and pulmonary blood flow, pulmonary infarction, acute respiratory distress syndrome and fatalities. Embolization of Lipiodol to brain and other major organs may occur. Avoid use of Lipiodol in patients with severely impaired lung function, cardiorespiratory failure, or right–sided cardiac overload. Perform radiological monitoring during the Lipiodol injection. Do not exceed the recommended maximum dose and rate of injection of Lipiodol. During lymphography to minimize the risk of pulmonary embolism obtain radiographic confirmation of intralymphatic (rather than venous) injection, and terminate the procedure when Lipiodol becomes visible in the thoracic duct or lymphatic obstruction is observed.

5.2 Hypersensitivity Reactions

Anaphylactoid and anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following Lipiodol administration. Avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to Lipiodol. Administer Lipiodol only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation; ensure continuous medical monitoring and maintain an intravenous access line. Most hypersensitivity reactions to Lipiodol occur within half an hour after administration. Delayed reactions can occur up to several days after administration. Observe patients for signs and symptoms of hypersensitivity reactions during and for at least 30 minutes following Lipiodol administration.

5.3 Exacerbation Of Chronic Liver Disease

Lipiodol hepatic intra-arterial administration can exacerbate the following conditions: portal hypertension and cause variceal bleeds due to obstruction of the intrahepatic portal channels by opening a pre sinusoidal anastomosis; hepatic ischemia and cause liver enzyme elevations, fever and abdominal pain; hepatic failure and cause ascites and encephalopathy. Hepatic vein thrombosis, irreversible liver insufficiency and fatalities have been reported. Procedural risks include vascular complications and infections.

5.4 Thyroid Dysfunction

Iodinated contrast media can affect thyroid function because of the free iodine content and can cause hyperthyroidism or hypothyroidism in predisposed patients. Patients at risk are those with latent hyperthyroidism and those with Hashimoto thyroiditis, or history of thyroid irradiation. As Lipiodol may remain in the body for several months, thyroid diagnostic results can be affected for up to two years after lymphography.

6.2 Postmarketing Experience

The following adverse reactions (Table 1) have been identified during post approval use of Lipiodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.The following adverse reactions are described in more detail in other sections of the prescribing information:
Pulmonary and cerebral embolism [see Warnings and Precautions (5.1)]
Hypersensitivity reactions [see Warnings and Precautions (5.2)]
Exacerbation of chronic liver disease [see Warnings and Precautions (5.3)]
Table 1: Adverse Reactions in the Postmarketing ExperienceSystem Organ ClassAdverse Reaction Endocrine disordershypothyroidism, hyperthyroidism, thyroiditisEye disordersretinal vein thrombosisGastrointestinal disordersnausea, vomiting, diarrheaGeneral disorders and administration site conditionsfever, pain, granulomaHepatobiliary disordershepatic vein thrombosisImmune system disordershypersensitivity, anaphylactic reaction, anaphylactoid reactionNervous system disorderscerebral embolismRespiratory, thoracic and mediastinal disorderspulmonary embolism, dyspnea, cough, acute respiratory distress syndromeUrinary system disordersrenal insufficiencyHysterosalpingographyAbdominal pain, foreign body reactions, exacerbation of pelvic inflammatory disease.LymphographyCardiovascular collapse, lymphangitis, thrombophlebitis, edema or exacerbation of preexisting lymphedema, dyspnea and cough, fever, iodism (headache, soreness of mouth and pharynx, coryza and skin rash), allergic dermatitis, lipogranuloma, delayed healing at the site of incision.Selective Hepatic Intra-arterial InjectionFever, abdominal pain, nausea, and vomiting are the most common reactions; other reactions include hepatic ischemia, liver enzymes abnormalities, transitory decrease in liver function, liver decompensation and renal insufficiency. Procedural risks include vascular complications and infections.

7.1 Interference With Iodine-Based Diagnostic Tests And Iodine-Based Radiotherapy

Following Lipiodol administration, ethiodized oil remains in the body for several months, and may interfere with thyroid function testing for up to two years. Ethiodized oil interferes with radioactive iodine uptake by thyroid tissue for several weeks to months and may impair visualization of thyroid scintigraphy and reduce effectiveness of iodine 131 treatment.

8.1 Pregnancy

Pregnancy Category CRisk SummaryThere are no adequate and well-controlled studies of Lipiodol effects in pregnant women. Use Lipiodol during pregnancy only if clearly needed.Human DataIt is not known whether Lipiodol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
The use of Lipiodol during pregnancy causes iodine transfer which may interfere with the thyroid function of the fetus and result in brain damage and permanent hypothyroidism. Institute thyroid function testing and careful medical monitoring of the neonate exposed to Lipiodol in utero.
Animal DataAnimal reproduction studies have not been conducted using the indicated routes of administration of Lipiodol. Lipiodol was not embryotoxic or teratogenic in rats after oral administration of up to 110 mg Iodine/kg each day between gestation days 6 to 17, or in rabbits after 4-5 intermittent (once every three days) oral administrations of 12.5 mg Iodine/kg between gestation days 6 to 18.

8.2 Nursing Mothers

No nonclinical lactation studies of Lipiodol have been reported.Lipiodol is excreted in human milk. Avoid use of Lipiodol in a nursing woman because of risk of hypothyroidism in nursing infants. If breastfeeding is continued the neonate’s thyroid function should be monitored.

8.3 Pediatric Use

For lymphography use a dose of minimum of 1 mL to a maximum of 6 mL according to the anatomical area to be visualized. Do not exceed 0.25 mL/kg. Administer the smallest possible amount of Lipiodol according to the anatomical area to be visualized.

8.4 Geriatric Use

There are no studies conducted in geriatric patients.

8.5 Renal Impairment

Prior to an intra-arterial administration of Lipiodol screen all patients for renal dysfunction by obtaining history and/or laboratory tests. Consider follow-up renal function assessments for patients with a history of renal dysfunction.

10 Overdosage

Overdose may lead to respiratory, cardiac or cerebral complications, which can potentially be fatal. Microembolisms to multiple organs may occur more frequently after overdose. Promptly initiate symptomatic treatment and support of vital functions.

11 Description

Lipiodol, ethiodized oil injection, is a sterile injectable radio-opaque agent. Each milliliter contains 480 mg of Iodine organically combined with ethyl esters of fatty acids of poppy seed oil. The precise structure of Lipiodol is unknown.Lipiodol is a sterile, clear, pale yellow to amber colored oil. Lipiodol has a viscosity of 34 – 70 mPa·s at 20°C, and a density of 1.28 g/cm3 at 20°C.

12.1 Mechanism Of Action

Ethiodized oil is an iodinated poppy seed oil based contrast agent.

12.3 Pharmacokinetics

Following intra-arterial administration of Lipiodol, ethiodized oil retained in normal hepatic parenchyma is phagocytized by the Kupffer cells of the liver and washed out via the hepatic lymphatic system in about 2 to 4 weeks. In HCC, retention in the liver tumor is prolonged, allowing re-imaging of the tumor for four weeks or longer.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential, or whether Lipiodol can affect fertility in males or females. Lipiodol did not demonstrate mutagenic potential in bacterial reverse mutation assays (in vitro), in a chromosomal aberration test in the mouse lymphoma assay (in vitro), and was negative in an in vivo micronucleus test in rats after intravenous injection of 479 mg I/kg.

16 How Supplied/Storage And Handling

Lipiodol is supplied in a box of one 10 mL ampoule, NDC 67684-1901-1.Store at controlled room temperature 15°-30°C (59°-86°F) [see USP, Controlled Room Temperature (CRT)].
Protect from light. Remove from carton only upon use.

* Please review the disclaimer below.